Loading clinical trials...
Loading clinical trials...
This is a Phase 2a open-label, single-arm study to evaluate the effects of DaxibotulinumtoxinA-lanm (DAXI) for Injection on the treatment of dynamic forehead lines (FHL) and glabellar lines (GL). App...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Revance Therapeutics, Inc.
NCT05481931 · Glabellar Frown Lines
NCT03985982 · Glabellar Frown Lines
NCT05146999 · Glabellar Frown Lines
NCT05894109 · Adjuvant Zinc May Increase the Efficacy of Botulinum Toxin, Zinc Supplementation for Botulinum Toxin Treatment of the Forehead, and more
NCT05148000 · Glabellar Frown Lines, Canthal Lines
Revance
Nashville, Tennessee
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions